drugset / Trial / NCT03254732
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks. Assessment of safety and tolerability of drug combination
Timeline
- Start
- 2017-07-14
- Primary completion
- 2019-05-07
- Completion
- 2020-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegargiminase | Protein / enzyme biologic | 36 mg/m2 | — |
| Subject | Pembrolizumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 2 mg/kg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |